Coming soon from Redeye: Updated website and features - Click here for more information

Orexo: Zubsolv Rx Data week 7, 2017

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.54% (5.57%), 4-week rolling average. The total number of Zubsolv tablets sold week 7 (6) reaching 321,491 (325,107). Zubsolv prescriptions (TRx) recorded a market share of 5.57% (5.59%), 4-week rolling average. Total number of prescriptions reaching 11,599 (11,659) during the week. The overall market (buprenorphine/naloxone) showed a y/y growth rate of 9.4% (8.9%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 11.5% (10.7%) (4-week rolling average).

We have adjusted our forecast for Orexos latest corporate bond buyback (nominal value of SEK 59 million), which adds SEK 2 million to net earnings in 2017 and 2018.

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-05-23 Update
2017-05-23 Update
2017-05-23 Update
2017-05-23 Update
2017-05-23 Update
2017-05-22 Update
2017-05-19 Update
2017-05-19 Update
2017-05-18 Update
2017-05-17 Update
2017-05-17 Update
2017-05-17 Update
2017-05-17 Update
2017-05-16 Analys
2017-05-16 Update
2017-05-12 Update
2017-05-12 Update
2017-05-12 Update
2017-05-11 Update
2017-05-11 Update
2017-05-10 Update
2017-05-10 Update
2017-05-10 Update
2017-05-10 Update
2017-05-10 Update